First Light Asset Management LLC Has $22.75 Million Holdings in Inari Medical, Inc. (NASDAQ:NARI)

First Light Asset Management LLC increased its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 120.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 472,384 shares of the company’s stock after buying an additional 258,444 shares during the quarter. Inari Medical accounts for about 2.0% of First Light Asset Management LLC’s investment portfolio, making the stock its 26th largest position. First Light Asset Management LLC owned 0.81% of Inari Medical worth $22,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of NARI. Dimensional Fund Advisors LP boosted its stake in shares of Inari Medical by 7.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock valued at $38,693,000 after purchasing an additional 41,555 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Inari Medical by 54.3% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 4,821 shares of the company’s stock valued at $313,000 after buying an additional 1,697 shares in the last quarter. Norges Bank bought a new stake in Inari Medical during the fourth quarter worth about $29,491,000. D.A. Davidson & CO. increased its holdings in shares of Inari Medical by 1.8% during the fourth quarter. D.A. Davidson & CO. now owns 10,570 shares of the company’s stock worth $686,000 after buying an additional 188 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Inari Medical by 47.0% in the fourth quarter. Assetmark Inc. now owns 10,454 shares of the company’s stock valued at $679,000 after acquiring an additional 3,344 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Trading Down 1.2 %

Shares of NARI opened at $43.17 on Tuesday. The stock has a market cap of $2.51 billion, a P/E ratio of -105.29 and a beta of 1.00. The stock’s 50-day moving average price is $47.81 and its two-hundred day moving average price is $46.13. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $69.40.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. The firm had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. As a group, equities analysts forecast that Inari Medical, Inc. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Robert W. Baird dropped their price target on Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a report on Wednesday, July 31st. Leerink Partners started coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price objective on the stock. William Blair assumed coverage on shares of Inari Medical in a research report on Thursday, July 25th. They set an “outperform” rating on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Inari Medical in a report on Monday, August 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research note on Wednesday, July 31st. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $58.44.

Insider Transactions at Inari Medical

In other Inari Medical news, Director William Hoffman sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00. Following the sale, the director now directly owns 805,359 shares in the company, valued at approximately $40,388,753.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director William Hoffman sold 20,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00. Following the completion of the sale, the director now owns 805,359 shares of the company’s stock, valued at $40,388,753.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the sale, the chief financial officer now directly owns 179,600 shares in the company, valued at $8,105,348. The disclosure for this sale can be found here. Insiders have sold a total of 155,520 shares of company stock valued at $8,111,707 over the last 90 days. 10.60% of the stock is owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.